Macrophage inhibitory cytokine 1, syncollin and thrombospondin-2 in pancreatic ductal adenocarcinoma and chronic pancreatitis differentiation - Takeaways - MDSpire

Macrophage inhibitory cytokine 1, syncollin and thrombospondin-2 in pancreatic ductal adenocarcinoma and chronic pancreatitis differentiation

  • By

  • Michalina Wieczorek

  • Lukasz Wieczorek

  • Anna Borkowska

  • Ewa Malecka-Wojciesko

  • June 26, 2026

  • 0 min

Share

  • 1

    Pancreatic ductal adenocarcinoma (PDAC) has a rising global incidence and is characterized by low survival rates.

  • 2

    Differentiating PDAC from chronic pancreatitis (CP) is challenging due to overlapping clinical and radiological features.

  • 3

    Serum biomarkers GDF15 and SYCN showed significant elevation in PDAC compared to CP and healthy controls, while TSP-2 did not.

  • 4

    The combined GDF15 + SYCN panel improved diagnostic performance for PDAC, achieving an AUC of 0.89.

  • 5

    GDF15 and SYCN are promising biomarkers for PDAC diagnosis, while TSP-2 has limited diagnostic utility.

Original Source(s)

Macrophage inhibitory cytokine 1, syncollin and thrombospondin-2 in pancreatic ductal adenocarcinoma and chronic pancreatitis differentiation

  • by Michalina Wieczorek, Lukasz Wieczorek, Anna Borkowska, Ewa Malecka-Wojciesko

  • June 26, 2026

Related Content

ESMO Breast Cancer 2026 Highlights Panel Discussion

Harold Burstein, MD, PhD; Sara Tolaney, MD, MPH; Erica L. Mayer, MD, MPH; Nancy Lin, MD; and Ana C. Garrido-Castro, MD discuss important breast cancer research presented at the 2026 ESMO Breast Cancer Congress.

  • June 26, 2026

  • 1 min
Algebraic evaluation of optimization in tumors classification with numerical assessments via a flask–react web interface

Epidemiology of bone cancer in Saudi Arabia: a nationwide population-based study (2004–2020)